At a glance
- Originator Eisai Co Ltd
- Class Antiasthmatics
- Mechanism of Action 5-lipoxygenase inhibitors; Thromboxane A2 synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Asthma
Most Recent Events
- 01 Aug 1996 Phase-II clinical trials for Asthma in Japan (PO)